Edition:
United States

BioInvent International AB (BINV.ST)

BINV.ST on Stockholm Stock Exchange

2.13SEK
15 Dec 2017
Change (% chg)

-0.02kr (-0.93%)
Prev Close
2.15kr
Open
2.15kr
Day's High
2.15kr
Day's Low
2.10kr
Volume
626,313
Avg. Vol
630,747
52-wk High
3.53kr
52-wk Low
1.95kr

Chart for

About

BioInvent International AB (BioInvent) is a Sweden-based biopharmaceutical company. The Company is engaged in the research and development of antibody-based drugs for the treatment of diseases, such as thrombosis, cancer and acute coronary artery disease. Its product range includes human antibodies, such as TB-402, TB-403,... (more)
No analyst recommendations are available for .

Overall

Beta: 0.92
Market Cap(Mil.): kr649.00
Shares Outstanding(Mil.): 304.70
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 198.20 16.04
EPS (TTM): -- -- --
ROI: -- -11.76 34.69
ROE: -- -36.72 15.46

BRIEF-Transgene Collaborates with BioInvent To Treat Solid Tumors

* BIOINVENT AND TRANSGENE COLLABORATE ON NEXT GENERATION ONCOLYTIC VIRUSES ENCODING AN ANTI-CTLA-4 ANTIBODY TO TREAT SOLID TUMORS

Dec 06 2017

BRIEF-Bioinvent posts Q3 net loss​

* Q3 ‍earnings after tax: SEK -21 (-29) million.​ Source text for Eikon: Further company coverage: (Stockholm Newsroom)

Oct 26 2017

BRIEF-Bioinvent CEO to step down amid increased focus on clinical development

* says both the board and Michael believe that it is a good time for a change in leadership, as the company is transitioning to a specific focus on clinical development and R&D

Oct 24 2017

BRIEF-The japanese patent office intends to grant Bioinvent's immune-oncology antibody patent

* The japanese patent office intends to grant bioinvent's important patent relating to the immune-oncology antibody bi-1206

Sep 12 2017

BRIEF-Bioinvent Q2 net loss decreases yr/yr

* Q2 earnings after tax: SEK -23 (-27) million. Source text for Eikon: Further company coverage: (Stockholm Newsroom)

Jul 26 2017

BRIEF-Bioinvent and ThromboGenics amending long-standing monoclonal antibody development agreement

* Bioinvent and ThromboGenics amending long-standing monoclonal antibody development agreement

Jul 10 2017

BRIEF-Bioinvent and Thrombogenics amend monoclonal antibody development agreement

* BIOINVENT AND THROMBOGENICS AMENDING LONG-STANDING MONOCLONAL ANTIBODY DEVELOPMENT AGREEMENT

Jul 10 2017

BRIEF-BioInvent and Thrombogenics amend monoclonal antibody development agreement

* Bioinvent and Thrombogenics amending long-standing monoclonal antibody development agreement Source text for Eikon: Further company coverage:

Jul 10 2017

Earnings vs. Estimates